Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | ACP3 | P15309 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28447924 | 1.00 | ALDH1A1 (0.57) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL28452365 | 1.00 | ALDH1A1 (0.57) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| Hydrochloric Acid SCHEMBL28443805 | 0.98 | ACP3 (0.58) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL29277735 | 0.90 | GPR88 (0.52) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL29277734 | 0.90 | GPR88 (0.52) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL17186397 | 0.86 | ALDH1A1 (0.68) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL17193735 | 0.86 | ALDH1A1 (0.68) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL17186621 | 0.86 | ALDH1A1 (0.68) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL17186620 | 0.86 | ALDH1A1 (0.68) | ALDH1A1ACP3PKMKMT2AGPR88 | |
| SCHEMBL17186493 | 0.86 | ALDH1A1 (0.68) | ALDH1A1ACP3PKMKMT2AGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305635-B1 | FORMOTEROL TARTRATE, PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20120108670-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2012-03-01 | — | — | US | disclosed |
| US-8110706-B2 | Formoterol tartrate process and polymorph | SUNOVION PHARMACEUTICALS INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110313199-A1 | PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | disclosed |
| US-7964753-B2 | Formoterol tartrate process and polymorph | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2305635-A2 | Formoterol tartrate process and polymorph | SEPRACOR, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110014246-A1 | AMORPHOUS ARFORMOTEROL L-(+)-TARTRATE | ACTAVIS GROUP PTC EHF (IS) | 2011-01-20 | — | — | US | disclosed |
| US-20100249459-A1 | Formoterol Tartrate Process and Polymorph | SEPRACOR INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100204336-A1 | Formoterol Tartrate Process and Polymorph | SEPRACOR INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-6720453-B2 | PURITY; THERMODYNAMICALLY STABLE | SEPRACOR INC. | 2004-04-13 | — | — | US | disclosed |
| EP-1082293-B1 | FORMOTEROL POLYMORPHS | SEPRACOR INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030149304-A1 | Formoterol tartrate polymorph | SEPRACOR INC. | 2003-08-07 | — | — | US | disclosed |
| EP-1093450-B1 | DESFORMOTEROL AND PROCESS FOR ITS PREPARATION | SEPRACOR INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6472563-B1 | RECRYSTALLIZATION FROM AQUEOUS ISOPROPYL ALCOHOL; HIGH PURITY; THERMODYNAMICALLY STABLE | SEPRACOR INC. | 2002-10-29 | — | — | US | disclosed |
| EP-0938467-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6268533-B1 | REACTING 4-BENZYLOXY-3-FORMAMIDOSTYRENE OXIDE WITH AN OPTICALLY PURE 4-METHOXY-.ALPHA.-METHYL-N-(PHENYLMETHYL)BENZENEETHANAMINE FOLLOWED BY REDUCTION TO PRODUCE FORMOTEROL | SEPRACOR INC. | 2001-07-31 | — | — | US | disclosed |
| US-6071971-A | FOR TREATING PULMONARY DISORDERS | SEPRACOR INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6040344-A | CRYSTALLINE R,R-FORMOTEROL L-(+)-TARTRATE. | SEPRACOR INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5965622-A | BRONCHODILATORS; HIGHLY SELECTIVE BETA 2-ADRENERGIC RECEPTOR AGONIST; RESPIRATORY DISORDERS, E.G. ASTHMA, BRONCHITIS; REDUCTION OF A PROTECTED NITRO DERIVATIVE; STEREOSPECIFIC | SEPRACOR INC. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249459-A1 | Formoterol Tartrate Process and Polymorph | ADRB1, ADRA1B, ADRA1A | ALDH1A1 2738/4885ACP3 350/4885PKM 3317/4885 |
| US-20110014246-A1 | AMORPHOUS ARFORMOTEROL L-(+)-TARTRATE | AGTR1, AGTR2, AGT | ALDH1A1 3465/4885ACP3 44/4885PKM 4772/4885 |
| US-20120108670-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | ADRB1, ADRA1B, ADRA1A | ALDH1A1 2738/4885ACP3 350/4885PKM 3317/4885 |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ADRB1, ADRB2, ADRA1A | ALDH1A1 1084/4885ACP3 484/4885PKM 3591/4885 |
| US-20030149304-A1 | Formoterol tartrate polymorph | ADRB1, ADRA1B, ADRA1A | ALDH1A1 2633/4885ACP3 286/4885PKM 3979/4885 |
| US-20110313199-A1 | PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ADRB2, ADRA2A, ADRB1 | ALDH1A1 1401/4885ACP3 2243/4885PKM 3026/4885 |
| US-20100204336-A1 | Formoterol Tartrate Process and Polymorph | ADRB1, ADRA1B, ADRA1A | ALDH1A1 2738/4885ACP3 350/4885PKM 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.